BioSim

Executive Summary

BioSim is the Spanish Biosimilars Association, a non-profit organization founded in 2003 and based in Barcelona. It represents over 20 pharmaceutical companies established in Spain that are involved in the research, development, production, and commercialization of biosimilar medicines. As the key industry voice in Spain, BioSim works to promote the use of biosimilars among healthcare professionals, patients, and policymakers, emphasizing their potential to improve patient access to biologics while reducing healthcare costs. The association also provides educational resources and advocacy to foster a favorable regulatory environment for biosimilars in Spain and across Europe. Through its activities, BioSim has contributed to the growing acceptance and uptake of biosimilars in Spain, which is now one of the leading markets in Europe for these medicines. The association regularly engages with the Spanish Medicines Agency (AEMPS) and the European Medicines Agency (EMA) to support evidence-based policies. Looking ahead, BioSim aims to further expand biosimilar adoption by addressing barriers such as physician reluctance and biosimilar switching. As the biosimilar pipeline grows, BioSim is well-positioned to support its members in navigating complex regulatory pathways and market dynamics, ensuring that patients benefit from affordable biologic therapies.

Upcoming Catalysts (preview)

• Q3 2026Biosimilars Congress Europe 202680% success
• Q2 2026Spanish National Biosimilar Adoption Guidelines Update60% success
• Q1 2026Launch of BioSim's Annual Market Report 202690% success